Term and Scope of Royalty Obligations Sample Clauses

Term and Scope of Royalty Obligations. Subject to Section ------------------------------------- 8.3.2 relating to discontinuance of royalty obligations and Section 13.1 relating to term of royalty obligations, royalties on each Licensed Product at the rate set forth in Section 7.3.1(a) shall continue until the expiration of the time set forth in Section 7.3.1. No royalties shall be due upon the sale or other transfer among Schering, its Affiliates or sublicensees, but in such cases the royalty shall be due and calculated upon Schering's or its Affiliates' or its sublicensees' Net Sales to the first independent third party. No royalties shall accrue on the disposition of Licensed Product by Schering, Affiliates or its sublicensees as samples (promotion or otherwise) or as donations (for example, to non-profit institutions or government agencies for a non-commercial purpose) or for clinical studies. Such sales by Schering shall not be included in the determination of Net Sales, during the period of time in which such third party sales are occurring.
Sample 1
AutoNDA by SimpleDocs
Term and Scope of Royalty Obligations. Royalties on Net Sales of each Licensed Product at the rate set forth in Section 3.2 shall continue until the expiration of the last to expire of the Patent Rights in the Territory. No royalties shall be due upon the sale or other transfer among Nanogen, its Affiliates or sublicensees, but in such cases the royalty shall be due and calculated upon Nanogen's or its Affiliates' or its sublicensees' Net Sales to the first independent third party.
Sample 1
Term and Scope of Royalty Obligations. Subject to the terms of Sections 4.3(b) and 8.1, royalties on each Licensed Product at the rate set forth in Section 3.2(a) shall continue until the expiration of the last applicable Licensed Patent Right incorporating a Valid Claim. No royalties shall be due upon the sale or other transfer among Schering, its Affiliates or sublicensees, but in such cases the royalty shall be due and calculated upon Schering's or its Affiliates' or its sublicensees' Net Sales to the first independent third party. No royalties shall accrue on the disposition of Licensed Product by Schering, its Affiliates or its sublicensees as donations (for example, to nonprofit institutions or government agencies for a non-commercial purpose) or for clinical studies.
Sample 1
Term and Scope of Royalty Obligations. Subject to the terms of Sections 4.3(b) and 8.1, royalties on each Licensed Product at the rate set forth in Section 3.2(a) shall continue until the expiration of the last applicable Licensed Patent Right incorporating a Valid Claim. No royalties shall be due upon the sale or other transfer among SP Ltd., its Affiliates or sublicensees, but in such cases the royalty shall be due and calculated upon SP Ltd's or its Affiliates' or its sublicensees' Net Sales to the first independent third party. No royalties shall accrue on the disposition of Licensed Product by SP Ltd., its Affiliates or its sublicensees as donations (for example, to nonprofit institutions or government agencies for a non-commercial purpose) or for clinical studies.
Sample 1
Term and Scope of Royalty Obligations. Royalties on each Licensed Product sold by or on behalf of AHPC, its Affiliates or their respective sublicensees, at the rates set forth in this Section 3.9 shall continue on a Licensed Product by Licensed Product and a country-by-country basis until the expiration of the Term of this Agreement in such country with respect to such Licensed Product as provided in Section 8.1 hereof. No royalties shall be due upon the sale or other transfer among AHPC, its Affiliates or sublicensees, but in such cases the royalty shall be due and calculated upon AHPC's or its Affiliates' or its sublicensees' Net Sales to the first independent Third Party.
Sample 1
Term and Scope of Royalty Obligations. Subject to the terms of Sections 4.3(b) and 14.1, royalties on each Licensed Product at the rate set forth in Section 3.2(a) shall continue on a country by country basis until the later of (i) ten (10) years from the First Commercial Sale of the first Licensed Product in the country or (ii) the expiration of the last applicable Licensed Patent Right incorporating a Valid Claim. No royalties shall be due upon the sale or other transfer among Schering, its Affiliates or sublicensees, but in such cases the royalty shall be due and calculated upon Schering's or its Affiliates' or its sublicensees' Net Sales to the first independent third party. No royalties shall accrue on the disposition of Licensed Product by Schering, its Affiliates or its sublicensees as donations (for example, to non-profit institutions or government agencies for a non-commercial purpose), or at minimal pricing for charitable purposes to financially disadvantaged patients, directly or indirectly, through Schering's "Commitment to Care" and successor programs, professional samples, or Licensed Product provided at no cost to any third party or for clinical studies.
Sample 1

Related to Term and Scope of Royalty Obligations

  • Duration of Royalty Obligations The royalty obligations of Licensee as to each Product shall terminate on a country-by-country and product-by-product basis concurrently with the expiration of:

  • Royalty Obligations Part 2.7(e) of the Disclosure Schedule contains a complete and accurate list and summary of all royalties, fees, commissions, and other amounts payable by the Seller to any Person (other than sales commissions paid to employees according to the Seller’s standard commissions plan) upon or for the sale, or distribution of any Seller Product or the use of any Seller IP.

  • Payment of Royalties To the best of Seller’s knowledge, all royalties and in-lieu royalties with respect to the Assets which accrued or are attributable to the period prior to the Effective Time have been properly and fully paid, or are included within the suspense amounts being conveyed to Buyer pursuant to Section 11.4.

  • Know-How Royalty Notwithstanding the provisions of Section 5.4.1(a), in countries where the sale of Product by Merck or its Related Parties would not infringe a Valid Patent Claim, Merck shall pay royalty rates that shall be set at [***] of the applicable royalty rate determined according to Section 5.4.1(a). Such royalties shall be calculated after first calculating royalties under Section 5.4.1(a).

  • Running Royalties Company shall pay to JHU a running royalty as set forth in Exhibit A, for each LICENSED PRODUCT(S) sold, and for each LICENSED SERVICE(S) provided, by Company or AFFILIATED COMPANIES, based on NET SALES and NET SERVICE REVENUES for the term of this Agreement. Such payments shall be made quarterly. All non-US taxes related to LICENSED PRODUCT(S) or LICENSED SERVICE(S) sold under this Agreement shall be paid by Company and shall not be deducted from royalty or other payments due to JHU. In order to insure JHU the full royalty payments contemplated hereunder, Company agrees that in the event any LICENSED PRODUCT(S) shall be sold to an AFFILIATED COMPANY or SUBLICENSEE(S) or to a corporation, firm or association with which Company shall have any agreement, understanding or arrangement with respect to consideration (such as, among other things, an option to purchase stock or actual stock ownership, or an arrangement involving division of profits or special rebates or allowances) the royalties to be paid hereunder for such LICENSED PRODUCT(S) shall be based upon the greater of: 1) the net selling price (per NET SALES) at which the purchaser of LICENSED PRODUCT(S) resells such product to the end user, 2) the NET SERVICE REVENUES received from using the LICENSED PRODUCT(S) in providing a service, or 3) the net selling price (per NET SALES) of LICENSED PRODUCT(S) paid by the purchaser. No multiple royalties shall be due or payable because any LICENSED PRODUCT(S) or LICENSED SERVICE(S) is covered by more than one claim of the PATENT RIGHTS or by claims of both the PATENT RIGHTS under this Agreement and “PATENT RIGHTS” under any other license agreement between Company and JHU. The royalty shall not be cumulative based on the number of patents or claims covering a product or service, but rather shall be capped at the rate set forth in Exhibit A.

  • Sublicense Fees Licensee will pay Sublicense Fees indicated in Section 3.1(e) of the Patent & Technology License Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

  • Minimum Royalties If royalties paid to Licensor do not reach the minimum royalty amounts stated in Section 3.3 of the Patent & Technology License Agreement for the specified periods, Licensee will pay Licensor on or before the Quarterly Payment Deadline for the last Contract Quarter in the stated period an additional amount equal to the difference between the stated minimum royalty amount and the actual royalties paid to Licensor.

  • Reports; Payment of Royalty During the Term following the First Commercial Sale of a Product, Merck shall furnish to Ambrx a quarterly written report for the Calendar Quarter showing the Net Sales of all Royalty Products subject to royalty payments sold by Merck and its Related Parties in the Territory for use in the Field during the reporting period and the royalties payable under this Agreement. Reports shall be due on the [***] day following the close of each Calendar Quarter. Royalties shown to have accrued by each royalty report shall be due and payable on the date such royalty report is due. Merck shall keep complete and accurate records in sufficient detail to enable the royalties payable hereunder to be determined.

  • Earned Royalties Subject to of Article 7 hereof, Licensee shall pay to Licensor for the rights granted hereunder a sum equal to one and [*****] of the Net Invoice Value of Trademarked Products Sold by Licensee (the "Royalties"). The Royalties shall be remitted in accordance with Section 7.4 of this Agreement. 6.2

  • Payment of Royalty If the Optionor and Optionee have formed the Joint Venture under Article 4.1 hereof, then until either the Optionee or Optionor ceases to have any interest in the Joint Venture and the Property, the Optionee and Optionor shall pay their proportionate shares(based on their respective undivided interests in the Joint Venture) of any royalty payable to any governmental body.

Time is Money Join Law Insider Premium to draft better contracts faster.